Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... drug discovery costs by 30-50% while accelerating timelines. Startups are increasingly leveraging machine ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other blue chip stocks to invest in at 52-week lows. For the first time since ...

Maps suffered a bug that effectively deleted the entire timeline history for many people. I was affected. Years and years of countries, cities, and places just gone from my phone, with seemingly ...

Regeneron is the second pharma group to sign ... Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.

Scientific research from Sewanhaka’s high schoolers is being recognized on the international level. While five students Sewanhaka Central High School students recently won awards for their ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...

Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websi Regeneron Pharmaceuticals, Inc. and Society ...